Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:CDXC
- CUSIP: N/A
- Web: N/A
- Market Cap: $125.34 million
- Outstanding Shares: 39,790,000
- 50 Day Moving Avg: $2.94
- 200 Day Moving Avg: $2.80
- 52 Week Range: $2.25 - $5.95
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 8.75
- P/E Growth: 0.00
- Annual Revenue: $23.93 million
- Price / Sales: 5.24
- Book Value: $0.25 per share
- Price / Book: 12.60
- Average Volume: 339,018 shs.
- Short Ratio: 12.13
Frequently Asked Questions for Chromadex Corp (OTCMKTS:CDXC)
What is Chromadex Corp's stock symbol?
Chromadex Corp trades on the OTCMKTS under the ticker symbol "CDXC."
How were Chromadex Corp's earnings last quarter?
Chromadex Corp (OTCMKTS:CDXC) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.05. The business earned $5.64 million during the quarter, compared to analysts' expectations of $5.60 million. View Chromadex Corp's Earnings History.
Where is Chromadex Corp's stock going? Where will Chromadex Corp's stock price be in 2017?
2 brokers have issued 12 month price targets for Chromadex Corp's shares. Their forecasts range from $6.00 to $6.00. On average, they expect Chromadex Corp's stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Chromadex Corp.
Who are some of Chromadex Corp's key competitors?
Some companies that are related to Chromadex Corp include Avid Technology (AVID), Viralytics Ltd Spon (VRACY), ADOCIA SPON ADR REPR 1 (ADOCY), Helius Medical Technologies (HSDT), Imageware Systems (IWSY), Essential Energy S (EEYUF), Barfresh Food Group (BRFH), Rmp Energy (OEXFF), Rubicon Minerals Corp. (RBYCF), PERPETUAL ENERGY I COM NPV (POST REV SPLIT) (PMGYF), One Group Hospitality (STKS), IntelGenx Technologies Corp. (IGXT), Catasys (CATS), OmniComm Systems (OMCM), Abengoa Sa (ABGOY), Trxade Group (TRXD), OptimizeRx (OPRX) and Acerus Pharmaceuti (TRLPF).
Who owns Chromadex Corp stock?
Chromadex Corp's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), Tieton Capital Management LLC (0.00%), Granite Investment Partners LLC (0.65%), Geode Capital Management LLC (0.00%), North Star Investment Management Corp. (0.39%) and TIAA CREF Investment Management LLC (0.00%). Company insiders that own Chromadex Corp stock include Frank L Jaksch Jr, Robert N Fried, Stephen R Allen and Troy Allen Rhonemus. View Institutional Ownership Trends for Chromadex Corp.
Who sold Chromadex Corp stock? Who is selling Chromadex Corp stock?
Chromadex Corp's stock was sold by a variety of institutional investors in the last quarter, including North Star Investment Management Corp., Morgan Stanley, Granite Investment Partners LLC and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Chromadex Corp.
Who bought Chromadex Corp stock? Who is buying Chromadex Corp stock?
Chromadex Corp's stock was purchased by a variety of institutional investors in the last quarter, including Tieton Capital Management LLC, Vanguard Group Inc., Teachers Advisors LLC, Geode Capital Management LLC and Segall Bryant & Hamill LLC. Company insiders that have bought Chromadex Corp stock in the last two years include Frank L Jaksch Jr, Robert N Fried, Stephen R Allen and Troy Allen Rhonemus. View Insider Buying and Selling for Chromadex Corp.
How do I buy Chromadex Corp stock?
Shares of Chromadex Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Chromadex Corp stock cost?
One share of Chromadex Corp stock can currently be purchased for approximately $3.15.
Consensus Ratings for Chromadex Corp (OTCMKTS:CDXC) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$6.00|
Analysts' Ratings History for Chromadex Corp (OTCMKTS:CDXC)
(Data available from 5/24/2015 forward)
|3/20/2017||HC Wainwright||Set Price Target||Buy||$6.00|
|1/3/2017||Rodman & Renshaw||Initiated Coverage||Buy||$6.00|
Earnings History for Chromadex Corp (OTCMKTS:CDXC)Earnings History by Quarter for Chromadex Corp (OTCMKTS:CDXC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/16/2017||Q4 2016||($0.01)||($0.06)||$5.60 million||$5.64 million||View||N/A|
|11/10/2016||Q3 2016||($0.03)||$5.01 million||View||Listen|
|8/11/2016||Q216||$0.01||$6.10 million||$8.80 million||View||Listen|
|5/12/2016||Q116||$0.01||$5.30 million||$7.30 million||View||Listen|
Earnings Estimates for Chromadex Corp (OTCMKTS:CDXC)
Current Year EPS Consensus Estimate: $0.16 EPS
Next Year EPS Consensus Estimate: $0.36 EPS
Dividend History for Chromadex Corp (OTCMKTS:CDXC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Chromadex Corp (OTCMKTS:CDXC)Insider Trades by Quarter for Chromadex Corp (OTCMKTS:CDXC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/19/2017||Stephen R Allen||Director||Buy||3,000||$3.20||$9,600.00|| |
|3/20/2017||Stephen R Allen||Director||Buy||2,000||$2.81||$5,620.00|| |
|12/12/2016||Frank L Jaksch Jr||CEO||Buy||2,000||$2.42||$4,840.00|| |
|9/1/2016||Frank L Jaksch Jr||CEO||Buy||1,500||$3.32||$4,980.00|| |
|9/1/2016||Robert N Fried||Director||Buy||15,000||$3.39||$50,850.00|| |
|6/20/2016||Troy Allen Rhonemus||COO||Buy||7,800||$3.47||$27,066.00|| |
Headline Trends for Chromadex Corp (OTCMKTS:CDXC)
Latest Headlines for Chromadex Corp (OTCMKTS:CDXC)
|ChromaDex's (CDXC) CEO Frank Jaksch on Q1 2017 Results - Earnings Call Transcript|
seekingalpha.com - May 12 at 9:47 PM
|ChromaDex reports 1Q loss|
finance.yahoo.com - May 11 at 9:52 PM
|Investor Network: ChromaDex Corporation to Host Earnings Call|
finance.yahoo.com - May 11 at 4:48 PM
|ChromaDex Reports First Quarter 2017 Financial Results|
finance.yahoo.com - May 11 at 4:48 PM
|ChromaDex to Report First Quarter 2017 Financial Results on Thursday, May 11, 2017|
finance.yahoo.com - May 4 at 4:22 PM
|ETFs with exposure to Chromadex Corp. : April 24, 2017|
finance.yahoo.com - April 24 at 4:08 PM
|ChromaDex to Showcase Novel Ingredient Science and Brand-Elevating Services at Ingredient Marketplace 2017|
finance.yahoo.com - April 11 at 10:35 AM
|ChromaDex to Present at the Cowen and Company’s 3rd Annual Future of the Consumer Conference: Convergence & Disruption on April 4, 2017|
finance.yahoo.com - March 29 at 12:21 PM
|ChromaDex (CDXC) Appoints Steven Rubin to its Board of Directors - StreetInsider.com|
www.streetinsider.com - March 28 at 4:02 PM
|ChromaDex (CDXC) Appoints Steven Rubin to its Board of Directors|
www.streetinsider.com - March 28 at 12:46 PM
|HC Wainwright Analysts Give Chromadex Corp (CDXC) a $6.00 Price Target|
www.americanbankingnews.com - March 21 at 3:40 PM
|Edited Transcript of CDXC earnings conference call or presentation 17-Mar-17 5:00pm GMT|
finance.yahoo.com - March 20 at 7:32 PM
|Zacks Investment Research Lowers Chromadex Corp (CDXC) to Sell|
www.americanbankingnews.com - March 20 at 5:37 PM
|ChromaDex's (CDXC) CEO Frank Jaksch on Q4 2016 Results - Earnings Call Transcript|
seekingalpha.com - March 17 at 9:50 PM
|ChromaDex Reports 2016 Record Revenue as Ingredient Sales Grew 34%|
www.nasdaq.com - March 16 at 5:33 PM
|Q4 2016 Chromadex Corp Earnings Release - After Market Close|
us.rd.yahoo.com - March 16 at 5:33 PM
|Chromadex Corp (CDXC) Downgraded to Sell at Zacks Investment Research|
www.americanbankingnews.com - March 13 at 10:06 AM
|ChromaDex to Report Year End 2016 Financial Results on Thursday, March 16, 2017|
finance.yahoo.com - March 10 at 5:12 PM
|A Letter from the ChromaDex Chief Executive Officer|
us.rd.yahoo.com - February 23 at 4:11 PM
|ChromaDex (CDXC) Says Study Published in PAIN Shows Nicotinamide Riboside is Effective Tool in Relieving Chemotherapy-Induced Peripheral Neuropathy|
www.streetinsider.com - February 23 at 2:22 AM
|ChromaDex (CDXC) Says Study Published in PAIN Shows Nicotinamide Riboside is Effective Tool in Relieving ... - StreetInsider.com|
www.streetinsider.com - February 22 at 9:20 PM
|Study Published in PAIN Reveals Nicotinamide Riboside is an Effective Tool in Relieving Chemotherapy-Induced Peripheral Neuropathy Induced by a Common Anticancer Agent|
finance.yahoo.com - February 22 at 12:11 PM
|6:31 am ChromaDex announces the publication of a study by U of Iowa researchers in the Journal of the International Association for the Study of Pain showing that NIAGEN Nicotinamide Riboside ameliorates chemotherapy-induced peripheral neur|
finance.yahoo.com - February 22 at 12:11 PM
|ChromaDex to Showcase Premier Innovation and Brand-Elevating Science at Engredea 2017|
finance.yahoo.com - February 21 at 2:26 PM
|CHROMADEX CORP. Files SEC form 8-K, Other Events|
biz.yahoo.com - February 17 at 6:00 PM
|ChromaDex (CDXC) Sees Q4 Revenue of $5.6M - StreetInsider.com|
www.streetinsider.com - February 16 at 9:02 AM
|ChromaDex Expects to Report Record Fourth Quarter as Revenue Increased Approximately 29%|
finance.yahoo.com - February 14 at 4:56 PM
|CHROMADEX CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits|
biz.yahoo.com - February 14 at 4:56 PM
|CHROMADEX CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - January 6 at 9:41 PM
|ChromaDex to Present at the ICR Conference 2017 on January 11, 2017|
finance.yahoo.com - January 4 at 5:15 PM
Chromadex Corp (CDXC) Chart for Wednesday, May, 24, 2017